{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T14:56:54Z","timestamp":1740149814858,"version":"3.37.3"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,7,21]],"date-time":"2021-07-21T00:00:00Z","timestamp":1626825600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,7,21]],"date-time":"2021-07-21T00:00:00Z","timestamp":1626825600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin J Gastroenterol"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1007\/s12328-021-01481-9","type":"journal-article","created":{"date-parts":[[2021,7,21]],"date-time":"2021-07-21T16:29:30Z","timestamp":1626884970000},"page":"1517-1524","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Successful multimodality treatment for advanced hepatocellular carcinoma with tumor thrombosis of the main portal trunk: a case study"],"prefix":"10.1007","volume":"14","author":[{"given":"Yumi","family":"Kosaka","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomokazu","family":"Kawaoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yutaro","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kei","family":"Amioka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kensuke","family":"Naruto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Yoshikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuwa","family":"Ando","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yosuke","family":"Suehiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Yamaoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasutoshi","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinsuke","family":"Uchikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Ono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masami","family":"Yamauchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michio","family":"Imamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keigo","family":"Chosa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuo","family":"Awai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasushi","family":"Nagata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuaki","family":"Chayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3409-2156","authenticated-orcid":false,"given":"Hiroshi","family":"Aikata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,7,21]]},"reference":[{"key":"1481_CR1","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1055\/s-2007-1007122","volume":"19","author":"JM Llovet","year":"1999","unstructured":"Llovet JM, Bru C, Bruix J, et al. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis. 1999;19:329\u201338.","journal-title":"Semin Liver Dis"},{"key":"1481_CR2","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/S0140-6736(18)30010-2","volume":"391","author":"A Forner","year":"2018","unstructured":"Forner A, Reig M, Bruix J, et al. Hepatocellular carcinoma. Lancet. 2018;391:1301\u201314.","journal-title":"Lancet"},{"key":"1481_CR3","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1002\/(SICI)1097-0142(19970515)79:10<1890::AID-CNCR8>3.0.CO;2-K","volume":"79","author":"E Ando","year":"1997","unstructured":"Ando E, Yamashita F, Tanaka M, et al. A novel chemotherapy for advanced hepatocellular carcinoma with tumor thrombosis of the main trunk of the portal vein. Cancer. 1997;79:1890\u20136.","journal-title":"Cancer"},{"key":"1481_CR4","doi-asserted-by":"publisher","first-page":"759","DOI":"10.2214\/ajr.167.3.8751696","volume":"167","author":"S Rossi","year":"1996","unstructured":"Rossi S, Di Stasi M, Buscarini E, et al. Percutaneous RF interstitial thermal ablation in the treatment of hepatic cancer. AJR Am J Roentgenol. 1996;167:759\u201368.","journal-title":"AJR Am J Roentgenol"},{"issue":"359","key":"1481_CR5","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1016\/S0140-6736(02)08649-X","volume":"18","author":"JM Llovet","year":"2002","unstructured":"Llovet JM, Real MI, Montana X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomized controlled trial. Lancet. 2002;18(359):1734\u20139.","journal-title":"Lancet"},{"key":"1481_CR6","first-page":"359","volume":"11","author":"BK Jang","year":"2005","unstructured":"Jang BK, Chung WJ, Park KS, et al. The efficacy of hepatic arterial infusion therapy for advanced hepatocellular carcinoma according to extrahepatic collateral feeding vessels. Korean J Hepatol. 2005;11:359\u201370.","journal-title":"Korean J Hepatol"},{"key":"1481_CR7","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1002\/cncr.21043","volume":"103","author":"DY Kim","year":"2005","unstructured":"Kim DY, Park W, Lim DH, et al. Three-dimensional conformal radiotherapy for portal vein thrombosis of hepatocellular carcinoma. Cancer. 2005;103:2419\u201326.","journal-title":"Cancer"},{"key":"1481_CR8","doi-asserted-by":"publisher","first-page":"1990","DOI":"10.1002\/cncr.21832","volume":"106","author":"S Obi","year":"2006","unstructured":"Obi S, Yoshida H, Toune R, et al. Combination therapy of intraarterial 5-fluorouracil and systemic interferon-alpha for advanced hepatocellular carcinoma with portal venous invasion. Cancer. 2006;106:1990\u20137.","journal-title":"Cancer"},{"key":"1481_CR9","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1007\/s00535-007-2099-8","volume":"42","author":"K Uka","year":"2007","unstructured":"Uka K, Aikata H, Takaki S, et al. Pretreatment predictor of response, time to progression, and survival to intraarterial 5-fluorouracil\/interferon combination therapy in patients with advanced hepatocellular carcinoma. J Gastroenterol. 2007;42:845\u201353.","journal-title":"J Gastroenterol"},{"key":"1481_CR10","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1056\/NEJMoa0708857","volume":"359","author":"JM Llovet","year":"2008","unstructured":"Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378\u201390.","journal-title":"N Engl J Med"},{"key":"1481_CR11","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","volume":"10","author":"AL Cheng","year":"2009","unstructured":"Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomized, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10:25\u201334.","journal-title":"Lancet Oncol"},{"key":"1481_CR12","doi-asserted-by":"publisher","first-page":"355","DOI":"10.3350\/kjhep.2010.16.4.355","volume":"16","author":"HY Kim","year":"2010","unstructured":"Kim HY, Kim JD, Bae SH, et al. A comparative study of high-dose hepatic arterial infusion chemotherapy and transarterial chemoembolization using doxorubicin for intractable, advanced hepatocellular carcinoma. Korean J Hepatol. 2010;16:355\u201361.","journal-title":"Korean J Hepatol"},{"key":"1481_CR13","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1159\/000315244","volume":"781","author":"K Ueshima","year":"2010","unstructured":"Ueshima K, Kudo M, Takita M, et al. Hepatic arterial infusion chemotherapy using low-dose 5-fluorouracil and cisplatin for advanced hepatocellular carcinoma. Oncology. 2010;781:148\u201353.","journal-title":"Oncology"},{"key":"1481_CR14","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1016\/j.jhep.2011.10.021","volume":"56","author":"K Takayasu","year":"2012","unstructured":"Takayasu K, Arii S, Kudo M, et al. Superselective transarterial chemoembolization for hepatocellular carcinoma. Validation of treatment algorithm proposed by Japanese guidelines. J Hepatol. 2012;56:886\u201392.","journal-title":"J Hepatol"},{"key":"1481_CR15","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/j.jhep.2012.11.009","volume":"58","author":"K Hasegawa","year":"2013","unstructured":"Hasegawa K, Kokudo N, Makuuchi M, et al. Comparison of resection and ablation for hepatocellular carcinoma: a cohort study based on a Japanese nationwide survey. J Hepatol. 2013;58:724\u20139.","journal-title":"J Hepatol"},{"key":"1481_CR16","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","volume":"389","author":"J Bruix","year":"2017","unstructured":"Bruix J, Qin S, Merle P, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomized, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;389:56\u201366.","journal-title":"Lancet"},{"key":"1481_CR17","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","volume":"391","author":"M Kudo","year":"2018","unstructured":"Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomized phase 3 non-inferiority trial. Lancet. 2018;391:1163\u201373.","journal-title":"Lancet"},{"key":"1481_CR18","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1080\/14737140.2019.1674141","volume":"19","author":"N Personeni","year":"2019","unstructured":"Personeni N, Rimassa L, Pressiani T, et al. Cabozantinib for the treatment of hepatocellular carcinoma. Expert Rev Anticancer Ther. 2019;19:847\u201355.","journal-title":"Expert Rev Anticancer Ther"},{"key":"1481_CR19","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/S1470-2045(18)30937-9","volume":"20","author":"AX Zhu","year":"2019","unstructured":"Zhu AX, Kang YK, Yen CJ, et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased alpha-fetoprotein concentrations (REACH-2): a randomized, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019;20:282\u201396.","journal-title":"Lancet Oncol"},{"key":"1481_CR20","first-page":"105","volume":"23","author":"T Fujii","year":"1993","unstructured":"Fujii T, Takayasu K, Muramatsu Y, et al. Hepatocellular carcinoma with portal tumor thrombus: analysis of factors determining prognosis. Jpn J Clin Oncol. 1993;23:105\u20139.","journal-title":"Jpn J Clin Oncol"},{"key":"1481_CR21","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1002\/ijc.23131","volume":"122","author":"J Matsui","year":"2008","unstructured":"Matsui J, Yamamoto Y, Funahashi Y, et al. E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition. Int J Cancer. 2008;122:664\u201371.","journal-title":"Int J Cancer"},{"key":"1481_CR22","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/638747","volume":"2014","author":"O Tohyama","year":"2014","unstructured":"Tohyama O, Maysui J, Kodama K, et al. Antitumor activity of lenvatinib (e7080): an angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models. J Thyroid Res. 2014;2014: 638747.","journal-title":"J Thyroid Res"},{"key":"1481_CR23","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/2045-824X-6-18","volume":"6","author":"Y Yamamoto","year":"2014","unstructured":"Yamamoto Y, Matsui J, Matsushima T, et al. Lenvatinib, an angiogenesis inhibitor targeting VEGFR\/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage. Vasc Cell. 2014;6:18.","journal-title":"Vasc Cell"},{"key":"1481_CR24","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1111\/hepr.13243","volume":"49","author":"A Hiraoka","year":"2019","unstructured":"Hiraoka A, Kumada T, Kariyama K, et al. Therapeutic of lenvatinib for unresectable hepatocellular carcinoma in clinical practice: multicenter analysis. Hepatol Res. 2019;49:111\u20137.","journal-title":"Hepatol Res"},{"key":"1481_CR25","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1002\/cncr.10694","volume":"95","author":"E Ando","year":"2002","unstructured":"Ando E, Tanaka M, Yamashita F, et al. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: analysis of 48 cases. Cancer. 2002;95:588\u201395.","journal-title":"Cancer"},{"key":"1481_CR26","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/s00535-014-0978-3","volume":"50","author":"DS Song","year":"2015","unstructured":"Song DS, Song MJ, Bae SH, et al. A comparative study between sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis. J Gastroenterol. 2015;50:445\u201354.","journal-title":"J Gastroenterol"},{"key":"1481_CR27","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1111\/hepr.13232","volume":"48","author":"T Kawaoka","year":"2018","unstructured":"Kawaoka T, Aikata H, Kobayashi T, et al. Comparison of hepatic arterial infusion chemotherapy between 5-fluorouracil-based continuous infusion chemotherapy and low-dose cisplatin monotherapy for advanced hepatocellular carcinoma. Hepatol Res. 2018;48:1118\u201330.","journal-title":"Hepatol Res"},{"key":"1481_CR28","doi-asserted-by":"publisher","first-page":"2090","DOI":"10.1093\/annonc\/mdw323","volume":"27","author":"M Ikeda","year":"2016","unstructured":"Ikeda M, Shimizu S, Sato T, et al. Sorafenib plus hepatic arterial infusion chemotherapy with cisplatin versus sorafenib for advanced hepatocellular carcinoma: randomized phase II trial. Ann Oncol. 2016;27:2090\u20136.","journal-title":"Ann Oncol"},{"key":"1481_CR29","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.radonc.2007.07.005","volume":"84","author":"R Toya","year":"2007","unstructured":"Toya R, Murakami R, Baba Y, et al. Conformal radiation therapy for portal vein tumor thrombosis of hepatocellular carcinoma. Radiother Oncol. 2007;84:266\u201371.","journal-title":"Radiother Oncol"},{"key":"1481_CR30","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1111\/hepr.12392","volume":"45","author":"H Fujino","year":"2015","unstructured":"Fujino H, Kimura T, Aikata H, et al. Role of 3-D conformal radiotherapy for major portal vein tumor thrombosis combined with hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma. Hepatol Res. 2015;45:607\u201317.","journal-title":"Hepatol Res"},{"key":"1481_CR31","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1159\/000486483","volume":"94","author":"K Kodama","year":"2018","unstructured":"Kodama K, Kawaoka T, Aikata H, et al. Comparison of outcome of hepatic arterial infusion chemotherapy combined with radiotherapy and sorafenib for advanced hepatocellular carcinoma patients with major portal vein tumor thrombosis. Oncology. 2018;94:215\u201322.","journal-title":"Oncology"},{"key":"1481_CR32","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382:1894\u2013905.","journal-title":"N Engl J Med"},{"key":"1481_CR33","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1007\/s00270-015-1123-2","volume":"38","author":"T Hasegewa","year":"2015","unstructured":"Hasegewa T, Yamakado K, Takaki H, et al. Portal venous stent placement for malignant portal venous stenosis or occlusion. Cardinovasc Intervent Radiol. 2015;38:1515\u201322.","journal-title":"Cardinovasc Intervent Radiol"},{"key":"1481_CR34","first-page":"453","volume":"50","author":"T Tsukamoto","year":"2003","unstructured":"Tsukamoto T, Hirohashi K, Kudo S, et al. Percutaneous transhepatic metallic stent placement for malignant portal vein stenosis. Hepatogastroenterology. 2003;50:453\u20135.","journal-title":"Hepatogastroenterology"},{"key":"1481_CR35","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1016\/S1051-0443(07)61699-6","volume":"12","author":"K Yamakado","year":"2001","unstructured":"Yamakado K, Nakatsuka A, Tanaka N, et al. Malignant portal venous obstruction treated by stent placement significant factors affecting patency. J Vasc Interv Radiol. 2001;12:1407\u201315.","journal-title":"J Vasc Interv Radiol"},{"key":"1481_CR36","first-page":"407","volume":"56","author":"H Takaki","year":"2009","unstructured":"Takaki H, Yamakado K, Nakatsuka A, et al. Stent placement for portal venous stenosis following major abdominal surgery. Hepatogastroenterology. 2009;56:407\u201310.","journal-title":"Hepatogastroenterology"},{"key":"1481_CR37","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s12072-015-9663-8","volume":"10","author":"JJ Luo","year":"2016","unstructured":"Luo JJ, Zhang ZH, Liu QX, et al. Endovascular brachytherapy combined with stent placement and transarterial chemoembolization for treatment of HCC with main portal vein tumor thrombus. Hepatol Int. 2016;10:185\u201395.","journal-title":"Hepatol Int"},{"key":"1481_CR38","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1016\/j.jvir.2017.02.014","volume":"28","author":"J Lu","year":"2017","unstructured":"Lu J, Guo JH, Zhu HD, et al. Safety and efficacy of irradiation stent placement for malignant portal vein thrombus combined with transarterial chemoembolization for hepatocellular carcinoma. J Vasc Interv Radiol. 2017;28:786\u201394.","journal-title":"J Vasc Interv Radiol"},{"key":"1481_CR39","first-page":"413","volume":"61","author":"T Ishikawa","year":"2014","unstructured":"Ishikawa T, Kubota T, Abe H, et al. Percutaneous transhepatic portal vein stent placement can improve prognosis for hepatocellular carcinoma patients with portal vein tumor thrombosis. Hepatogastroenterology. 2014;61:413\u20136.","journal-title":"Hepatogastroenterology"}],"container-title":["Clinical Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-021-01481-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12328-021-01481-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-021-01481-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,13]],"date-time":"2021-09-13T15:17:35Z","timestamp":1631546255000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12328-021-01481-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,21]]},"references-count":39,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["1481"],"URL":"https:\/\/doi.org\/10.1007\/s12328-021-01481-9","relation":{},"ISSN":["1865-7257","1865-7265"],"issn-type":[{"type":"print","value":"1865-7257"},{"type":"electronic","value":"1865-7265"}],"subject":[],"published":{"date-parts":[[2021,7,21]]},"assertion":[{"value":"14 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Kazuaki Chayama has received honoraria from Bristol-Myers Squibb, MSD K.K., AbbVie Inc., Gilead Sciences, Dainippon Sumitomo Pharma and Mitsubishi Tanabe and research funding from Dainippon Sumitomo Pharma, MSD K.K, AbbVie Inc,\u00a0Eisai, Toray, Otsuka, Chugai, Takeda, Roche, Mitsubishi Tanabe and Bristol-Byers Squibb.\u00a0Michio Imamura has received research funding from Bristol-Myers Squibb. Other authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures followed have been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human rights"}},{"value":"Informed consent was obtained from all patients for being included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}